|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
0.4150 USD |
+3.72% | -0.95% | -51.69% | |
April 10, 2025 at 05:42 pm EDT
This article is reserved for members Unlock the article: REGISTER NOW!
© MT Newswires – 2025
|
Shuttle Pharmaceuticals Files Provisional US Patent to Treat Prostrate Cancer |
05:42pm |
MT |
|
Shuttle Pharmaceuticals Files Provisional Patent Application For PSMA Ligand Conjugates To Treat Prostate Cancer |
04:52pm |
RE |
|
Shuttle Pharmaceuticals Holdings, Inc. Approves the Appointment of Anatoly Dritschilo, M.D., as Chief Scientific Officer, Effective March 30, 2025 |
Mar. 31 |
CI |
|
Shuttle Pharmaceuticals Holdings Inc – On March 21, Enters Consulting Agreement With Bowery Consulting – SEC Filing |
Mar. 25 |
RE |
|
Shuttle Pharma Announces Closing Of $5.75 Million Underwritten Offering |
Mar. 13 |
RE |
|
Shuttle Pharma Announces Appointment Of Christopher Cooper As Interim Co-CEO To Enhance Business Activities |
Mar. 12 |
RE |
|
Shuttle Pharmaceuticals Holdings, Inc. Appoints Christopher Cooper as Interim Co-CEO |
Mar. 12 |
CI |
|
Shuttle Pharmaceuticals Holdings Offers Up To 10,000,000 Shares Of Common Stock |
Mar. 05 |
RE |
|
Shuttle Pharmaceuticals Holdings Enters $2 Million Revolving Loan Agreement |
Feb. 28 |
RE |
|
Shuttle Pharmaceuticals Holdings, Inc. Announces Director Changes |
Feb. 28 |
CI |
|
Shuttle Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 |
Feb. 26 |
CI |
|
Shuttle Pharmaceuticals Holdings, Inc. Auditor Raises ‘Going Concern’ Doubt |
Feb. 25 |
CI |
|
Shuttle Pharmaceuticals Holdings, Inc. Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient |
Nov. 26 |
CI |
|
Shuttle Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 |
Nov. 13 |
CI |
|
Shuttle Pharmaceuticals Prices $4.5 Million Public Offering |
24-10-30 |
MT |
|
Shuttle Pharmaceuticals Starts Phase 2 Trial of Radiation Sensitizer in Glioblastoma Patients; Shares Rise |
24-10-29 |
MT |
|
Shuttle Pharmaceuticals Holdings, Inc. Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma |
24-10-29 |
CI |
|
Top Premarket Gainers |
24-10-29 |
MT |
|
Shuttle Pharmaceuticals Soars Premarket Following Completion of Phase 2 Glioblastoma Trial Site Enrollment |
24-10-29 |
MT |
|
Shuttle Pharmaceuticals Holdings, Inc. Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma |
24-10-28 |
CI |
|
Shuttle Pharmaceuticals Holdings, Inc. announced that it expects to receive $1.3 million in funding |
24-10-13 |
CI |
|
Shuttle Pharmaceuticals Launches Equity Offering |
24-09-20 |
MT |
|
Shuttle Pharmaceuticals Holdings, Inc. Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma |
24-09-16 |
CI |
|
Wall Street Set to Open Lower Wednesday as Nvidia Drags Down Markets |
24-09-04 |
MT |
|
Nvidia Weighs Down Markets as US Futures Trend Lower in Wednesday’s Premarket Session |
24-09-04 |
MT |
SHPH: Dynamic Chart
Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company. The Company is focused on improving the outcomes of cancer patients treated with radiation therapy (RT). It is developing a pipeline of products designed to address cancer therapies as well as to extend to the new applications of radiation therapy. Its product candidates include Ropidoxuridine (IPdR), Ropidoxuridine and Tipracil (IPdR/TPI), SP-1-161, SP-2-225, and SP-1-303. Ropidoxuridine (IPdR) is its lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. Ropidoxuridine and Tipracil (IPdR/TPI) is undergoing preclinical development for use as a radiation sensitizer for rectal cancers. SP-1-161 is a pre-clinical candidate lead histone deacetylase (HDAC) inhibitor, a radiation sensitizing candidate product. SP-2-225 is a pre-clinical class II b selective HDAC inhibitor that affects histone deacetylase HDAC6.
More about the company
}
